Title:Hyper-coagulopathy State in COVID-19: A Pivotal Challenge
Volume: 19
Issue: 3
Author(s): Najmeh Nameh Goshay Fard, Atena Vaghf, Ekhlas Torfi, Saeid Shahrabi and Seyed Mohammad Sadegh Pezeshki*
Affiliation:
- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Keywords:
COVID-19, SARS-CoV-2, coagulopathy, thrombosis, Anticoagulation, ARDS.
Abstract:
Background: The novel SARS-CoV-2 has caused a global pandemic. COVID-19 infection
is described by the adverse impact on the population’s health and economy. Coagulopathy is
associated with various thrombotic complications and disease severity. Therefore, this review aims
to elucidate the pathophysiology of this coagulopathy.
Methods: Relevant English language literature was searched and retrieved from the Google Scholar
search engine and PubMed database. We used “COVID-19”, “SARS-CoV-2”, “Coagulopathy”,
“Thrombosis”, “Anticoagulation”, and “ARDS” as keywords.
Results: Several studies showed that the primary targets of SARS-CoV-2 are pneumocytes, immune
cells, and vascular endothelial cells. Coagulopathy appears to induce more thrombotic complications
than hemorrhagic events. The critically ill patients stimulate the coagulopathy state and
thrombosis complication through cytokine storm, systemic inflammation, complement cascade, and
platelets. Accordingly, thromboembolic complications cause mortality among COVID-19-infected
patients and can negatively affect disease management outcomes and treatment.
Conclusion: A pivotal clinical feature of acute COVID-19 infection is coagulopathy and prothrombotic
events, which are associated with excessive arterial and venous thrombosis, microvascular
thrombosis, and adverse clinical outcomes. Therefore, adopting an approach for preventing, treating,
and reducing thrombotic and bleeding events in these patients is necessary.
